410 related articles for article (PubMed ID: 34713239)
1. A Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies.
Zittersteijn HA; Harteveld CL; Klaver-Flores S; Lankester AC; Hoeben RC; Staal FJT; Gonçalves MAFV
Front Genome Ed; 2020; 2():617780. PubMed ID: 34713239
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetics of β-thalassemia: A narrative review.
Jaing TH; Chang TY; Chen SH; Lin CW; Wen YC; Chiu CC
Medicine (Baltimore); 2021 Nov; 100(45):e27522. PubMed ID: 34766559
[TBL] [Abstract][Full Text] [Related]
3. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.
Traxler EA; Yao Y; Wang YD; Woodard KJ; Kurita R; Nakamura Y; Hughes JR; Hardison RC; Blobel GA; Li C; Weiss MJ
Nat Med; 2016 Sep; 22(9):987-90. PubMed ID: 27525524
[TBL] [Abstract][Full Text] [Related]
4. Genome editing approaches to β-hemoglobinopathies.
Brusson M; Miccio A
Prog Mol Biol Transl Sci; 2021; 182():153-183. PubMed ID: 34175041
[TBL] [Abstract][Full Text] [Related]
5. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
Paschoudi K; Yannaki E; Psatha N
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
[TBL] [Abstract][Full Text] [Related]
6. Clinical genome editing to treat sickle cell disease-A brief update.
Zarghamian P; Klermund J; Cathomen T
Front Med (Lausanne); 2022; 9():1065377. PubMed ID: 36698803
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin.
Ravi NS; Wienert B; Wyman SK; Bell HW; George A; Mahalingam G; Vu JT; Prasad K; Bandlamudi BP; Devaraju N; Rajendiran V; Syedbasha N; Pai AA; Nakamura Y; Kurita R; Narayanasamy M; Balasubramanian P; Thangavel S; Marepally S; Velayudhan SR; Srivastava A; DeWitt MA; Crossley M; Corn JE; Mohankumar KM
Elife; 2022 Feb; 11():. PubMed ID: 35147495
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic inactivation of ERF reactivates γ-globin expression in β-thalassemia.
Bao X; Zhang X; Wang L; Wang Z; Huang J; Zhang Q; Ye Y; Liu Y; Chen D; Zuo Y; Liu Q; Xu P; Huang B; Fang J; Lao J; Feng X; Li Y; Kurita R; Nakamura Y; Yu W; Ju C; Huang C; Mohandas N; Li D; Zhao C; Xu X
Am J Hum Genet; 2021 Apr; 108(4):709-721. PubMed ID: 33735615
[TBL] [Abstract][Full Text] [Related]
9. Genome editing strategies for fetal hemoglobin induction in beta-hemoglobinopathies.
Demirci S; Leonard A; Tisdale JF
Hum Mol Genet; 2020 Sep; 29(R1):R100-R106. PubMed ID: 32406490
[TBL] [Abstract][Full Text] [Related]
10. Using Clustered Regularly Interspaced Short Palindromic Repeats gene editing to induce permanent expression of fetal hemoglobin in β-thalassemia and sickle cell disease: A comparative meta-analysis.
Quagliano A; Acevedo D; Hardigan P; Prasad S
Front Med (Lausanne); 2022; 9():943631. PubMed ID: 36250099
[TBL] [Abstract][Full Text] [Related]
11. Recent advance on genome editing for therapy of β-hemoglobinopathies.
Liu JW; Hong T; Qin X; Liang YM; Zhang P
Yi Chuan; 2018 Feb; 40(2):95-103. PubMed ID: 29428902
[TBL] [Abstract][Full Text] [Related]
12. Wake-up Sleepy Gene: Reactivating Fetal Globin for β-Hemoglobinopathies.
Wienert B; Martyn GE; Funnell APW; Quinlan KGR; Crossley M
Trends Genet; 2018 Dec; 34(12):927-940. PubMed ID: 30287096
[TBL] [Abstract][Full Text] [Related]
13. Combined approaches for increasing fetal hemoglobin (HbF) and
Finotti A; Gambari R
Front Genome Ed; 2023; 5():1204536. PubMed ID: 37529398
[TBL] [Abstract][Full Text] [Related]
14. Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of β-hemoglobinopathies.
Venkatesan V; Christopher AC; Rhiel M; Azhagiri MKK; Babu P; Walavalkar K; Saravanan B; Andrieux G; Rangaraj S; Srinivasan S; Karuppusamy KV; Jacob A; Bagchi A; Pai AA; Nakamura Y; Kurita R; Balasubramanian P; Pai R; Marepally SK; Mohankumar KM; Velayudhan SR; Boerries M; Notani D; Cathomen T; Srivastava A; Thangavel S
Mol Ther Nucleic Acids; 2023 Jun; 32():671-688. PubMed ID: 37215154
[TBL] [Abstract][Full Text] [Related]
15. Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies.
Perrine SP; Pace BS; Faller DV
Hematol Oncol Clin North Am; 2014 Apr; 28(2):233-48. PubMed ID: 24589264
[TBL] [Abstract][Full Text] [Related]
16. Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34
Lamsfus-Calle A; Daniel-Moreno A; Antony JS; Epting T; Heumos L; Baskaran P; Admard J; Casadei N; Latifi N; Siegmund DM; Kormann MSD; Handgretinger R; Mezger M
Sci Rep; 2020 Jun; 10(1):10133. PubMed ID: 32576837
[TBL] [Abstract][Full Text] [Related]
17. Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies.
Testa U
Ann Hematol; 2009 Jun; 88(6):505-28. PubMed ID: 19011856
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9-based multiplex genome editing of BCL11A and HBG efficiently induces fetal hemoglobin expression.
Han Y; Tan X; Jin T; Zhao S; Hu L; Zhang W; Kurita R; Nakamura Y; Liu J; Li D; Zhang Z; Fang X; Huang S
Eur J Pharmacol; 2022 Mar; 918():174788. PubMed ID: 35093321
[TBL] [Abstract][Full Text] [Related]
19. Original Research: A case-control genome-wide association study identifies genetic modifiers of fetal hemoglobin in sickle cell disease.
Liu L; Pertsemlidis A; Ding LH; Story MD; Steinberg MH; Sebastiani P; Hoppe C; Ballas SK; Pace BS
Exp Biol Med (Maywood); 2016 Apr; 241(7):706-18. PubMed ID: 27022141
[TBL] [Abstract][Full Text] [Related]
20. Targeting fetal hemoglobin expression to treat β hemoglobinopathies.
Steinberg MH
Expert Opin Ther Targets; 2022 Apr; 26(4):347-359. PubMed ID: 35418266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
